Biomarker Discovery and Validation
A fundamental aspect of personalised healthcare is that laboratory tests can improve patient prognosis and predict response of individual patient treatment. Developing a biomarker alongside a new compound, which can be used for patient selection, will enable a reduction in size of a phase III trial by up to 50%. This can radically reduce costs and time to market. More importantly, the development of a companion diagnostic that allows correct targeting of the therapy to the right patients can greatly increase the treatments likelihood of commercial success. We can partner with customers from discovery to commercialisation to provide specific translational genomic services including: |
Almac Addresses Leading Cancer Specialists at All-Ireland Conference
|
With emphasis and advancements in personalised healthcare, the need for validated biomarkers is an increasing necessity. 
